To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination.

ABSTRACT:

Introduction

Coronavirus disease 2019 (COVID-19) has had an enormous impact worldwide, and vaccination is believed to be the method that will control the pandemic. Several types of vaccines developed using different platforms have been authorized, but the immunogenicity and reactogenicity of heterologous prime-boost vaccination with different vaccines remain largely unclear.

Areas covered

Electronic databases including PubMed, Embase, medRxiv, Research Square, and SSRN were searched to investigate the immunogenicity and reactogenicity associated with heterologous vaccination.As of 30 June 2021, four trials including 1,862 participants were identified. Heterologous administration of BNT162b2 (BNT) in ChAdOx1 (ChAd)-primed participants (ChAd/BNT) showed noninferior immunogenic

SUBMITTER: Chiu NC 

PROVIDER: S-EPMC8425437 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature